X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1999) 1999
Newsletter (631) 631
Publication (204) 204
Book Review (34) 34
Book / eBook (10) 10
Book Chapter (10) 10
Data Set (3) 3
Dissertation (3) 3
Newspaper Article (2) 2
Web Resource (2) 2
Conference Proceeding (1) 1
Magazine Article (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1608) 1608
cytochrome p-450 (1228) 1228
index medicus (1020) 1020
pharmacology & pharmacy (1015) 1015
cytochrome p-450 enzyme system - metabolism (755) 755
research (592) 592
metabolism (546) 546
male (526) 526
female (484) 484
physiological aspects (466) 466
cytochrome p450 (437) 437
animals (415) 415
cytochrome p-450 cyp2c8 (408) 408
pharmacokinetics (399) 399
cytochrome p-450 enzyme system - genetics (374) 374
drug interactions (365) 365
enzymes (350) 350
microsomes, liver - enzymology (332) 332
adult (313) 313
toxicology (301) 301
aryl hydrocarbon hydroxylases - genetics (297) 297
pharmacogenetics (287) 287
reports (284) 284
in-vitro (279) 279
middle aged (279) 279
human liver-microsomes (266) 266
microsomes, liver - metabolism (266) 266
genetic aspects (260) 260
genotype (247) 247
cytochrome p-450 cyp2c9 (241) 241
aryl hydrocarbon hydroxylases - metabolism (237) 237
drugs (229) 229
microsomes, liver - drug effects (227) 227
biochemistry & molecular biology (224) 224
cytochrome p-450 enzyme inhibitors (224) 224
metabolites (200) 200
drug metabolism (198) 198
kinetics (198) 198
analysis (197) 197
liver (195) 195
cyp2c8 (193) 193
hydroxylation (190) 190
expression (185) 185
universities and colleges (183) 183
inhibition (176) 176
aged (175) 175
polymorphism, genetic (173) 173
enzyme inhibitors - pharmacology (170) 170
genetic polymorphisms (167) 167
cancer (162) 162
in vitro techniques (160) 160
cytochrome (156) 156
biotransformation (155) 155
cytochrome p-450 cyp3a (155) 155
cyp3a4 (150) 150
polymorphism (147) 147
rats (138) 138
paclitaxel (137) 137
pharmacology (135) 135
aryl hydrocarbon hydroxylases (134) 134
identification (131) 131
recombinant proteins - metabolism (131) 131
isoenzymes - metabolism (130) 130
health aspects (128) 128
polymorphism, single nucleotide (128) 128
cytochrome p-450 cyp3a - metabolism (122) 122
drug-drug interactions (120) 120
cyp2c9 (115) 115
substrate specificity (113) 113
liver - enzymology (112) 112
alleles (109) 109
cytochrome p-450 cyp2c19 (108) 108
medicine (108) 108
dose-response relationship, drug (106) 106
drug-metabolism (106) 106
mass spectrometry (106) 106
microsomes (106) 106
polymorphisms (106) 106
liver - metabolism (105) 105
gemfibrozil (102) 102
gene expression (101) 101
p-glycoprotein (101) 101
cells, cultured (100) 100
oncology (99) 99
plasma-concentrations (98) 98
care and treatment (97) 97
genes (97) 97
aryl hydrocarbon hydroxylases - antagonists & inhibitors (95) 95
steroid 16-alpha-hydroxylase (95) 95
pharmaceutical preparations - metabolism (93) 93
area under curve (90) 90
chromatography, high pressure liquid (90) 90
young adult (90) 90
gene frequency (89) 89
article (88) 88
cytochrome p-450 enzyme system - biosynthesis (88) 88
induction (88) 88
genetics & heredity (87) 87
oxidation-reduction (86) 86
risk factors (86) 86
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Journal Article
Journal Article
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 2016, Volume 44, Issue 8, pp. 1364 - 1371
The glucose-lowering drug pioglitazone undergoes hepatic CYP2C8-mediated biotransformation to its main metabolites. The antiplatelet drug clopidogrel is... 
IN-VITRO | PHARMACOKINETICS | DEPENDENT INHIBITOR | SIMVASTATIN ACID | SLCO1B1 POLYMORPHISM | PHARMACOLOGY & PHARMACY | CERIVASTATIN | TRANSPORTING POLYPEPTIDE 1B1 | TYPE-2 DIABETES-MELLITUS | CYTOCHROME-P450 3A4 | DRUG-DRUG INTERACTIONS | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Area Under Curve | Humans | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Thiazolidinediones - administration & dosage | Thiazolidinediones - pharmacokinetics | Platelet Aggregation Inhibitors - blood | Young Adult | Hypoglycemic Agents - blood | Drug Interactions | Hypoglycemic Agents - administration & dosage | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Pharmacogenomic Variants | Ticlopidine - administration & dosage | Adult | Female | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Cytochrome P-450 CYP2C8 - metabolism | Platelet Aggregation Inhibitors - adverse effects | Hypoglycemic Agents - pharmacokinetics | Drug Administration Schedule | Risk Assessment | Administration, Oral | Genotype | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Thiazolidinediones - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Phenotype | Finland | Cytochrome P-450 CYP2C8 - genetics | Hypoglycemic Agents - adverse effects | Thiazolidinediones - blood | Ticlopidine - blood
Journal Article
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2018, Volume 104, Issue 3, pp. 495 - 504
The oxidation of montelukast is mainly mediated by cytochrome P450 (CYP) 2C8, but other mechanisms may contribute to its disposition. In healthy volunteers, we... 
GEMFIBROZIL | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | MARKEDLY INCREASES | PHARMACOLOGY & PHARMACY | ACUTE CORONARY SYNDROMES | LEUKOTRIENE-RECEPTOR ANTAGONIST | CYP2C8 SUBSTRATE PIOGLITAZONE | DRUG-DRUG INTERACTIONS | Cytochrome P-450 CYP2C8 Inhibitors - administration & dosage | Inactivation, Metabolic | Quinolines - blood | Acetates - adverse effects | Acetates - blood | Humans | Leukotriene Antagonists - pharmacokinetics | Substrate Specificity | Male | Clopidogrel - administration & dosage | Healthy Volunteers | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Drug Interactions | Leukotriene Antagonists - administration & dosage | Computer Simulation | Platelet Aggregation Inhibitors - administration & dosage | Pharmacogenomic Variants | Adult | Female | Cytochrome P-450 CYP2C8 - metabolism | Prasugrel Hydrochloride - administration & dosage | Leukotriene Antagonists - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Pharmacogenetics | Oxidation-Reduction | Risk Assessment | Cytochrome P-450 CYP2C8 Inhibitors - adverse effects | Prasugrel Hydrochloride - adverse effects | Cross-Over Studies | Acetates - administration & dosage | Models, Biological | Leukotriene Antagonists - blood | Clopidogrel - adverse effects | Cytochrome P-450 CYP2C8 - genetics | Quinolines - adverse effects | Acetates - pharmacokinetics | Research | Basic Medicine | Farmakologi och toxikologi | Medical and Health Sciences | Pharmacology and Toxicology | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal Article